I’m out in Hawaii working on some defense consulting and was just reading up on some of the latest DNA research…

Apparently, if you have abnormally strong bone density, or a high tolerance to pain, you may be able to cash-in big time by licensing your DNA.

Though before you jump to conclusions about your ability to withstand ungodly amounts of pain, you may want to check with your doctor to make sure you have one of these rare – and valuable – genetic mutations.

I don’t mean mutant X-men that are “walking among us.” I mean people like Timothy Dreyer – a 25-year-old with bones so dense, he can probably get hit by a car and leave the car more damaged.

Call him lucky. Or call it sclerosteosis – otherwise known as “Dreyer’s Condition,” so rare, it’s named after Timothy himself.

The result of uncommon deviations in DNA, only about 100 people in the entire world have it.

You might see where I’m going with this…

Dreyer’s rare mutation, along with others, are getting the attention of drug companies such as Amgen and Genentech.

They figure that studying genetic conditions such as these – and replicating their power – could potentially lead to DNA-based solutions for osteoporosis, managing pain, and lowering cholesterol. That’s huge.

Andreas Grauer, Amgen’s global development lead for a new osteoporosis drug, considers Dreyer’s mutation “a gift from nature” and that “it is our obligation to turn it into something useful.”

Rare mutations or not – these “disorders” have launched something of a major space race in the sector for drug companies to access databases of genetic information. The goal: Use the data to develop new drugs to treat these maladies.

One of the other big players, Genentech, is collaborating with Silicon Valley startup 23andMe. And Google’s biotechnology firm Calico is working with Ancestry.com, mining data from a pool of one million DNA samples to discover the root of longevity.

We’re entering an age where researching DNA can help us understand how to control pain… what makes some people live longer than others… and how these tools can help us benefit the human race.

And on the path to uncovering these secrets, there will be some serious money circulating through the biotech industry.

Ben Benoy

Ben Benoy
Editor, BioTech Intel Trader

New Update on the Markets!

Harry Dent shares details on his latest prediction for the markets and the new dangers that lie just ahead for Americans:   “This is no longer a question of ‘if,’ but simply a… Read More>>
Ben Benoy
Ben Benoy is a veteran of the U.S. Marine Corps and has been an active retail trader since 2006. He identifies investment opportunities based on key social media trends. He first identified the concept in 2008 and has since developed a tool for tracking investment “chatter” between social media users. His proprietary Social Media Stock Sentiment system has developed into a state-of-the-art platform that identifies and classifies chatter about stocks through algorithms and other indicators to forecast stock-price direction. Ben’s track record speaks for itself — over the past 12 months, his system boasts a win rate of 82.2% on 112 stock trades.